Edition:
United States

Onxeo SA (C4X.PA)

C4X.PA on Paris Stock Exchange

4.25EUR
26 May 2017
Change (% chg)

€0.98 (+29.97%)
Prev Close
€3.27
Open
€3.37
Day's High
€4.47
Day's Low
€3.36
Volume
4,624,149
Avg. Vol
236,592
52-wk High
€4.47
52-wk Low
€2.00

Latest Key Developments (Source: Significant Developments)

Onxeo announces allowance of U.S. patent for Livatag in hepatocellular carcinoma
Wednesday, 10 May 2017 01:05pm EDT 

May 10 (Reuters) - ONXEO SA :ONXEO ANNOUNCES ALLOWANCE OF U.S. PATENT FOR LIVATAG® IN HEPATOCELLULAR CARCINOMA.USPTO NOTICE OF ALLOWANCE RECEIVED FOR PATENT RELATED TO SPECIFIC ROUTE OF ADMINISTRATION FOR LIVATAG PROVIDES PROTECTION OF RELATED CLAIMS UNTIL 2032.  Full Article

Onxeo Q1 revenue up 55 pct to 1.2 million euros
Wednesday, 26 Apr 2017 12:30pm EDT 

April 26 (Reuters) - Onxeo SA ::Q1 revenue up 55 pct to EUR 1.2 million ($1.3 million) .Cash position of EUR 21.7 million at March 31, 2017.  Full Article

Onxeo FY net loss widens to 22.7 million euros
Tuesday, 7 Mar 2017 12:50pm EST 

Onxeo SA : FY revenue EUR 4.4 million ($4.65 million) versus EUR 3.5 million year ago . FY operating loss of EUR 23.2 million versus loss of EUR 22.4 million year ago . FY net loss EUR 22.7 million versus loss of EUR 19.4 million year ago . Cash and cash equivalents of EUR 29.2 million at December 31, 2016 . Enrolment for the phase III Livatag study in advanced primary liver cancer completed on schedule to deliver preliminary results mid-2017 Further company coverage: [C4X.PA] ($1 = 0.9454 euros) (Gdynia Newsroom) ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;)).  Full Article

Onxeo announces another positive DSMB recommendation for Livatag
Monday, 21 Nov 2016 12:00pm EST 

Onxeo SA : Announces 9th positive DSMB recommendation to continue Livatag relive phase III trial in HCC .Nine consecutive positive DSMB recommendations reinforce acceptable safety profile of Livatag.  Full Article

Onxeo SA Q3 revenues up at 1.23 mln euros
Tuesday, 25 Oct 2016 12:00pm EDT 

Onxeo Sa : Revenues for Q3 of 2016 amounted to 1.23 million euros ($1.34 million) compared to 1.1 million euros in Q3 of 2015 .12.5 million euros capital increase successfully completed.  Full Article

Onxeo issues 5,434,783 new shares for 12.5 million euros
Friday, 30 Sep 2016 03:54am EDT 

Onxeo SA :Capital increase through the issue of 5,434,783 new ordinary shares for an amount of 12.5 million euros ($13.98 million).  Full Article

BRIEF-Onxeo H1 net loss narrows to 11.2 million euros (July 28)
Friday, 29 Jul 2016 07:44am EDT 

Removes reference to Livatag in headline of July 28 brief item.Onxeo SA : H1 net loss of 11.2 million euros ($12.40 million) versus loss of 11.3 million euros year ago . H1 revenue 1.8 million euros versus 1.5 million euros year ago . Livatag phase III trial in HCC: 80 pct of patients randomized . First development steps of new oral formulation of Beleodaq .19.6 million euros cash-on-hand as of June 30, 2016.  Full Article

Onxeo Livatag H1 net loss narrows to 11.2 million euros
Thursday, 28 Jul 2016 12:00pm EDT 

Onxeo SA : H1 net loss of 11.2 million euros ($12.40 million) versus loss of 11.3 million euros year ago . H1 revenue 1.8 million euros versus 1.5 million euros year ago . Livatag phase III trial in HCC: 80 pct of patients randomized . First development steps of new oral formulation of Beleodaq .Eur 19.6m cash-on-hand as of June 30, 2016.  Full Article

Onxeo signs exclusive license agreement with Pint Pharma
Wednesday, 27 Jul 2016 12:00pm EDT 

Onxeo SA : Signs exclusive license agreement with Pint Pharma for commercialization of Beleodaq in PTCL in South America .Onxeo to receive upfront payment, regulatory and commercial milestones, and sales royalties for a total deal value greater than USD 20 million.  Full Article

Onxeo reports positive data for Livatag
Sunday, 17 Apr 2016 08:00pm EDT 

Onxeo SA:Reported the final data from a study aiming to confirm the mechanism of action of Livatag.Results demonstrated that the bio-distribution of oxorubicin Transdrug (Livatag) nanoparticles showed a preferential affinity for the liver and an increased exposure in plasma compared to free doxorubicin.  Full Article

More From Around the Web

BRIEF-Onxeo gets 10th positive DSMB recommendation to continue Livatag relive phase III trial in HCC

* ONXEO ANNOUNCES 10TH POSITIVE DSMB RECOMMENDATION TO CONTINUE LIVATAG® RELIVE PHASE III TRIAL IN HCC Source text for Eikon: Further company coverage: (Gdynia Newsroom)